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ABSTRACT
Warfarin is an effective preventative treatment for arterial and venous thromboembolism, but requires
individualised dosing due to its narrow therapeutic range and high individual variation. Many machine
learning techniques have been demonstrated in this domain. This study evaluated the accuracy of the
most promising algorithms on the International Warfarin Pharmacogenetics Consortium dataset and a
novel clinical dataset of South African patients. Support vectors and linear regression were amongst
the top performers in both datasets and performed comparably to recent stacked ensemble approaches,
whilst neural networks were one of the worst performers in both datasets. We also introduced genetic
programming to automatically optimise model architectures and hyperparameters without human
guidance. Remarkably, the generated models were found to match the performance of the best models
hand-crafted by human experts. Finally, we present a novel software framework (Warfit-learn) for
warfarin dosing research. It leverages the most successful techniques in preprocessing, imputation,
and parallel evaluation, with the goal of accelerating research and making results in this domain more
reproducible.
Keywords Warfarin · machine learning · genetic programming · Python · supervised learning · anticoagulant ·
pharmacogenetics · software
1 Introduction
Many individuals suffer from blood clots that lead to arterial and venous thromboembolism. The standard method for
treating these conditions is the use of anticoagulant drugs such as vitamin K antagonists, the most widely used of which
is warfarin. Whilst effective, the drug has a narrow therapeutic range and severe side-effects at extreme concentrations.
This makes the precise dosing of warfarin an important concern for clinicians. Unfortunately, warfarin metabolism
differs across individuals based on age, weight, genetics, diet, drug interactions, and various pre-existing conditions
[1, 2]. To standardise the process of anticoagulant monitoring, the World Health Organisation adopted the international
normalised ratio (INR) [3]. INR has become the standard measurement for anticoagulation monitoring around the world
[4].
Many studies [5, 6, 7, 8, 9, 10, 11, 12] have looked at applying statistical models to the problem of individualised
warfarin dosing. Accurate models improve the ability of clinicians to prescribe the correct warfarin doses to their
patients, whilst minimising the time required to do so. They also reduce the risk of severe haemorrhaging in patients
and the number of visits required to establish a therapeutic dose [13, 14, 15]. Unfortunately, warfarin datasets are small
and noisy, requiring the use of specialised data transformations and highly-optimised learning algorithms. Breakthrough
techniques are of significance to the medical research community and could lead to improvements in decision support
for those administering warfarin therapy.
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The learning algorithm chosen to produce the dosing model has a notable impact on accuracy and robustness. Moreover,
the precise hyperparameters chosen for the algorithm can drastically affect performance. Unfortunately, replicating
the precise methodology of previous studies has proven difficult, as no standards for preprocessing, imputation, data
stratification, and evaluation existed prior to this study. We introduce a new software framework (Warfit-learn) to
address these problems and validate it by comparing a variety of established and novel techniques on two different
warfarin datasets.
1.1 Related work
1.1.1 International warfarin pharmacogenetics consortium (IWPC)
The seminal work in warfarin dose estimation with pharmacogenetic data made use of 5052 patient records from the
initial version of the dataset utilised by later studies [16]. Researchers split the dataset randomly with an 80/20 ratio
into derivation and validation sets. The study selected the two key metrics that would come to be used in almost all
future work—mean absolute error (MAE) and percentage of patients within 20% of the therapeutic dose (PW20). They
found that a multiple linear regression technique yielded better results than the existing clinical algorithms, with an
MAE of 8.5± 1.7 mg/week in the validation cohort [16].
1.1.2 Liu et al. 2015
A notable study is that of Liu et al. in 2015 [5], which compared the average performance of 9 learning algorithms
on the IWPC dataset [17]. They removed patients missing height, weight, age, or genotype data, and patients not
at a stable warfarin dose—leaving 4798 patients remaining. Using libraries in the R language, they implemented 9
algorithms. They obtained the average performance of each algorithm in terms of PW20 and MAE with 100 rounds of
80/20 re-sampling from the filtered dataset. The focus of their study was evaluating a range of off-the-shelf algorithms
across dosage ranges and racial groups, but their top results (PW20 = 46.35%, MAE = 8.84) in the combined cohort set
an initial benchmark for performance on the IWPC data.
1.1.3 Ma et al. 2018
Another notable study is that of Ma et al. in late 2018 [12], which made advances using ensemble techniques and
improved imputation of missing data. Utilising the same IWPC dataset [17], Ma et al. imputed missing weight and
height values using a linear regression model. For imputing height, the variables were weight, race, and sex. For
imputing weight, they were height, race, and sex. They imputed missing values for the VKORC1 rs9923231 genotype
using the IWPC’s formula [18] based on race and linkage disequilibrium in VKORC1. Even after excluding outliers,
5743 subjects remained in the data set, resulting in a cohort nearly 20% greater than that of Liu et al. The raw warfarin
dose was square rooted to compensate for the skewed distribution of the variable. The researchers made use of a stacked
generalisation (stacking) framework to implement heterogeneous ensembles. Results were obtained through 100 rounds
of 80/20 re-sampling. Their findings suggest that stacked generalisation ensembles are significantly more accurate than
the existing isolated models on the IWPC dataset. Crucially, however, their stacked ensembles were given access to
far more parameters than the standalone models. Although they appear to have successfully utilised these additional
parameters, the inconsistency of this methodology means care should be taken when extrapolating from the results.
1.2 Model optimisation
The most common approach to model development is for an expert to repeatedly train models with various learning
algorithms and tweak their hyperparameters until performance is maximised. Ensemble methods–such as bagging,
boosting, and stacking–combine the outputs from several models to obtain better overall performance on unseen data.
This has been found to increase model performance in a number of warfarin dosing studies [5, 19, 8, 12]. Another
approach is the use of automatic machine learning (autoML), which employs meta-algorithms to automate the task of
optimisation.
In the past, autoML approaches have focused on optimising subsets of the machine learning pipeline [20]. Grid
search is a common form of hyperparameter optimisation based on a brute-force search of algorithm hyperparameters,
with the drawback of computational complexity. Conversely, random evaluation within the search space typically
discovers an effective hyperparameter set more quickly than exhaustive search [21]. A trade-off between the expensive
(but comprehensive) exhaustive search and the efficient (but uncertain) random evaluation is desired. A well-known
approach to this trade-off is evolutionary algorithms. Indeed, the use of genetic programming—a subset of evolutionary
algorithms—has been found to produce better models than human experts in a number of tasks [22, 23, 24, 25, 26, 27].
This promising avenue to autoML was explored in our paper.
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1.3 Genetic programming
Genetic programming emulates the process of natural selection as an optimisation strategy. In the context of this
study, the smallest components are machine learning algorithms and data processors. Each is encoded as a gene, with
parameters changing according to defined mutation and crossover rates. As with biological evolution, successful genes
propagate through the population and the most successful combinations of those genes seed the next generation [28].
This increases performance over time. By simulating many generations with well-chosen evolutionary hyperparameters
and population sizes, novel meta-algorithms with high accuracy can be produced. Genetic programming has been
shown to develop effective systems in a number of mathematical and computational domains [24, 25, 26, 27].
This study made use of the open-sourced Tree-based Pipeline Optimisation Tool (TPOT) to generate high-performing
models through genetic programming [23]. The TPOT framework was developed atop the Distributed Evolutionary
Algorithms in Python framework [29]. Each individual in the population is a tree-based machine learning pipeline.
Each node in the tree is a pipeline operator, which can be (1) a preprocessor, (2) a decomposer, (3) a feature selector,
or (4) a supervised learning algorithm. All of these operators are based on Scikit-learn [30] implementations. These
pipelines handle the data from feature extraction through to hyperparameter optimisation. The pipeline operators (and
their parameters) are encoded as a gene sequence, which evolves through the genetic programming process [23].
To prevent a tendency toward overly-complex pipelines, TPOT makes use of Pareto optimisation to optimise two
objectives simultaneously—maximising pipeline accuracy, whilst minimising pipeline complexity (measured as the
number of operators). Over many generations of evolution, TPOT’s implementation of the genetic programming
algorithm optimises the pipelines by adding new pipeline operators that improve fitness, and by removing redundant or
detrimental pipeline operators. The most accurate overall pipeline is saved as the representative pipeline at the end of a
TPOT run [23]. In other domains, TPOT has been shown to produce a significant improvement over basic machine
learning methods, with little involvement from users [23]. This study utilised TPOT to automatically evolve optimal
architectures and hyperparameters for warfarin dose estimation. The resulting estimators performed on par with those
manually optimised by machine learning experts.
2 Materials and methods
An illustration of the study’s methodology can be found in Figure 1 and highlights where our Warfit-learn software
framework was applied.
2.1 Datasets
Two datasets of warfarin records were used for this study. The standard IWPC dataset was used primarily for comparing
new techniques to those in existing literature, whilst a novel dataset from South Africa was used to evaluate how well
estimators generalised to a different clinical context. Both datasets have similar distributions of weekly warfarin dose,
INR, and age (see Table 1).
The International Warfarin Pharmacogenetics Consortium (IWPC) dataset [17] of 6256 patients has been used in a
number of notable studies [5, 7, 16, 12] and is the standard reference point for new approaches to automated warfarin
dosing. The dataset was compiled collaboratively and includes data from 22 research groups from 9 countries [16]. The
dataset is publicly available at pharmgkb.org/downloads.
The novel dataset was provided by PathCare, a private pathology group in South Africa. Unlike the IWPC dataset, no
pharmacogenetic data is available and very limited clinical data is present. A total of 4621 patients from the dataset
achieved their target INR range and were considered in this study (see Table 1). As with the IWPC dataset, patients
were de-identified prior to distribution. To guarantee the confidentiality of the data, only the authors had access to it
during the study. Ethical approval was obtained from the Science Research Ethics Committee at the University of Cape
Town and the project was sanctioned by the PathCare Research Committee. To protect the patients, the data is not
publicly available.
2.2 Data cleaning
For the IWPC dataset, this study replicated the work of Ma et al. [12] for filtering the patient records into a viable
cohort. This was done to verify their approach and to provide a consistent methodology for performance comparisons.
The process is detailed in their paper and in the source code of this study.
In this domain, missing data has typically been handled by either dropping whole records [5] or imputing missing
values [12, 11, 16]. Because the IWPC data is limited in size, dropping missing values leads to significant data loss
3
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Figure 1: An illustration of the methodology applied in this study, highlighting where our Warfit-learn software
framework was utilised and how a collection of estimators were evaluated across multiple datasets.
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Table 1: Analysis of the characteristics of the International Warfarin Pharmacogenetics Consortium (IWPC) subjects
and subjects from a novel South African dataset (PathCare) included in this study.
IWPC PathCare
Size 5741 4621
Warfarin dose (mg/week)
Mean 31.97 29.63
Median 28.0 27.50
Range 2.1 – 230.0 0.0 – 210.0
Standard deviation 16.77 16.04
Therapeutic INR
Mean 2.15 2.46
Median 2.34 2.40
Range 0.0 – 6.1 1.8 – 3.9
Standard deviation 0.82 0.33
Age Count % Count %
10 - 19 15 0.3 2 0.0
20 - 29 130 2.3 31 0.7
30 - 39 249 4.3 106 2.3
40 - 49 580 10.1 276 6.0
50 - 59 1133 19.7 490 10.6
60 - 69 1401 24.4 942 20.4
70 - 79 1539 26.8 1143 24.7
80 - 89 660 11.5 1127 24.4
90+ 34 0.6 204 4.4
Sex Count % Count %
Females 2466 43.0 2443 52.9
Males 3275 57.0 2178 47.1
Missing 0 0 0 0
Note: These are the cohorts after the preprocessing and imputation stages.
and is detrimental to performance. This study leveraged the most successful imputation techniques from previous
work—missing values for VKORC1 rs9923231 were imputed using the IWPC’s formula [18] based on race and linkage
disequilibrium, whilst missing height and weight were imputed with a regression model as per the work of Ma et al.
[12]. This process is built into the Warfit-learn preprocessing module.
2.3 Parameter selection
For the purposes of direct comparison to baseline, this study used the same parameter set defined by the IWPC [17]
and utilised by Liu et al. [5]. For the PathCare dataset, three parameter sets were evaluated using standard regression
techniques. The top-performing parameter set was selected and used for further evaluation. This set included the sex
and age of the patients; as well as records of their aspirin, paracetamol, and amiodarone use; and their history of atrial
fibrillation, deep vein thrombosis, and heart-valve replacement. All categorical parameters were vectorised into sparse
format so that the resulting feature set was purely numerical.
2.4 Preprocessing
The input features were scaled prior to training using the Scikit-learn implementation of StandardScaler—which
scales the data to unit variance. This desensitised the algorithms to the magnitudes of features. In both datasets, the
weekly dose (in mg) was transformed to its square root in order to correct for the skewed distributions. This was then
set as the target feature during training. During evaluation, the model predictions were squared and compared with the
original values–maintaining clinical relevance. Warfit-learn provides the option to perform this rooting and squaring
automatically.
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Table 2: Continued: Analysis of the characteristics of the International Warfarin Pharmacogenetics Consortium (IWPC)
subjects and subjects from a novel South African dataset (PathCare) included in this study.
IWPC PathCare
Height (cm)
Mean 167.98 -
Median 167.64 -
Range 125 – 202 -
Standard deviation 10.58 -
Weight (kg)
Mean 78.79 -
Median 76.0 -
Range 30 – 238 -
Standard deviation 22.32 -
Race (OMB) Count % Count %
White 3095 53.9 - -
Asian 1515 26.4 - -
Black 665 11.6 - -
Missing / mixed race 466 8.1 - -
VKORC1 Genotype (Imputed) Count % Count %
A/A 1695 29.5 - -
A/G 2058 35.8 - -
G/G 1884 32.8 - -
Unknown 104 1.8 - -
CYP2C9 Genotype Count % Count %
*1/*1 4230 73.7 - -
1/*2 755 13.2 - -
1/*3 482 8.4 - -
1/*5 0 0.0 - -
1/*6 0 0.0 - -
2/*2 58 1.0 - -
2/*3 68 1.2 - -
3/*3 20 0.3 - -
Unknown 128 2.2 - -
Indications Count % Count %
Enzyme inducer* 61 1.1 - -
Amiodarone 280 4.9 131 2.8
Smoker 482 8.4 - -
Notes: These are the cohorts after the preprocessing and imputation stages. The OMB racial categories were used in the
IWPC dataset and are defined by the 1997 Office of Management and Budget (OMB) standards for the U.S. Census
Bureau. * = carbamazepine, phenytoin, rifampin, rifampicin.
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2.5 Learning algorithms used
A basic linear regression model–similar to that of the IWPC [16]–was required as a baseline for model performance.
This was compared against many of the best-performing algorithms described by Liu et al. [5] and Ma et al. [12].
All algorithms were implemented using the Scikit-learn library [30] in Python 3, with the use of MLxtend [31] to
implement stacked ensembles. The implementation details and key hyperparameters can be found in Table 3.
2.6 Clinical and statistical metrics
Appropriate metrics were chosen to assess both the clinical and statistical accuracy of the models. An important clinical
consideration is that INR has a therapeutic range of ±0.5 in most patients [32] and using tighter target ranges for
maintenance dosing does not achieve any therapeutic advantage [33]. The chosen metrics accounted for that, and were
consistent with metrics used in related studies—allowing direct results comparisons. Moreover, the use of multiple
metrics for performance (one clinically-relevant, the other statistically-relevant) is a worthwhile methodology to employ
as it prevents the kind of systemic overfitting that occurs in other domains where a single metric is dominant.
1. Mean absolute error (MAE) is used widely across warfarin estimation studies [5, 6, 7, 34, 8, 9, 10, 11, 12].
MAE =
∑n
i=1 |yi − yˆi|
n
(1)
where yi is the actual dose and yˆi is the predicted dose.
2. Percentage of patients with dose estimates within 20% of the actual therapeutic dose (PW20) was used
by a number of notable studies [16, 10, 9, 5, 12]. It reflects the fact that being within 0.5 points of the target
INR is clinically sufficient [33].
PW20 =
∑n
i=1 f(pi)
n
× 100% (2)
where f(pi) for patient pi is 1 if 0.8yi < yˆi < 1.2yi, else 0; yˆi is the predicted dose, and yi is the true
therapeutic dose.
2.7 Evaluation protocol
Monte Carlo Cross-Validation (MCCV) was performed using the standard train_test_split function in Scikit-learn.
This performs resampling without replacement. All models were trained and evaluated using 100 iterations of MCCV
for each filtered dataset. In each iteration, the data was randomly split into a training set and a testing set in an 80/20
ratio. The model was then fit on the training set and evaluated in terms of PW20 and MAE on the testing set. The means
of these results and 95% confidence intervals were calculated for each model on each dataset based on the percentile
method.
2.8 Warfit-learn software library
Extending past studies in warfarin dose prediction required the development of a host of data cleaning and preprocessing
tools, evaluation routines, and scoring functions. To remove the need for repeating this effort in future work, this study
implements a new software framework for Python-based development of warfarin dose estimation models. The aim
of this library is to allow researchers to more easily replicate and extend the work of their colleagues in this domain.
This can help to reduce confusion about methodology and enhance reproducibility. The library focuses on four areas,
namely:
1. Seamless dataset loading, cleaning, and preprocessing.
2. Standardised implementations of scoring functions.
3. Multithreaded model training and evaluation using standardised resampling techniques.
4. Full interoperability with the Python scientific stack [35], Pandas [36], and Scikit-learn [30].
This makes it possible to replicate studies on the IWPC data with only a beginner’s level of Python experience.
Supervised learning models can be constructed using the popular Scikit-learn implementations, which are handled
natively by the framework. Libraries that extend the Scikit suite—such as MLxtend [31]—can be used directly with
minimal configuration. Parallel processing on a user-defined number of CPU cores is used to achieve speedup on the
resampling performed during evaluation and is wrapped in a user-friendly function. Functions for metrics like percentage
of patients within 20% of therapeutic dose (PW20) are implemented and automatically called during evaluation. Final
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results are produced as Pandas dataframes, which can be exported to CSV files or LaTeX tables with a single command.
The entire framework is available as open source software at http://pypi.org/project/warfit-learn under a
GNU GPLv3 license. All results for this study were obtained using the above tools in version 0.1 of Warfit-learn.
2.9 Optimisation with genetic programming
TPOT [23] was used to generate high-performing machine learning pipelines through genetic programming. In each
run, a preprocessed version of the dataset was given as input to TPOT and many generations of computation yielded the
best performers. TPOT accepts bespoke scoring functions as its evolutionary fitness function. The functions for PW20
and MAE were tested, as was a hybrid of the two:
hybrid =
PW20
MAE2
(3)
Many instances of TPOT were run on a multi-core machine using different evolutionary hyperparameters. The number
of generations ranged from 50 to 1000, the number of offspring from 5 to 100, and the k used in k-fold cross-validation
from 5 to 30. Some runs used the raw weekly dose as the target feature and others used the square root of weekly dose.
Over all the instances run on both datasets, the best performers (according to final validation scores within TPOT) were
evaluated against the human-optimised algorithms described in other studies.
3 Results and discussion
The performance of all estimators is compared across datasets in Table 4.
3.1 Validation of methodology
The methodology of this study was validated by referencing the results of previous work on warfarin dose estimation.
The original IWPC study reported an MAE of 8.5 mg/week (95% CI: 8.1–8.6) for their linear regression (LR) model
[16]. However, they processed the cohort differently. The study by Ma et al. evaluated models on an identical dataset to
our study, reporting an MAE of 8.53 (95% CI: 8.08–8.99) for their LR model [12]. By comparison, the MAE for the
LR model in this study was 8.59 mg/week (95% CI: 8.11–9.05). This indicates that our preprocessing and evaluation
methodology were valid. It also justifies the original IWPC finding that, when adequate preprocessing is performed,
linear regression produces outstanding results on the IWPC dataset [16]. This, coupled with its easy interpretability,
makes LR hard to rule out as the default warfarin estimation model. However, as datasets grow in size and variety, LR
can fail to model some relationships that more complex approaches succeed in capturing. It also tends to be less robust
to unusual examples than ensemble approaches, which could challenge its clinical applicability.
3.2 Performance of traditional techniques
Support vector regression (SV and SVR in Table 4) was a top-performing algorithm, whilst the neural network (NN)
was one of the worst performing algorithms. The relative performance of the NN and SVR models was similar to that
reported by Liu et al. [5]. Their NN (MAE 9.82, PW20 41.27) was by far their worst performer, whilst their SVR
(MAE 8.96, PW20 45.88) was one of their best performers. Similarly, this study’s NN (MAE 9.36, PW20 43.12) was
the worst-performing standalone algorithm by a considerable margin, whilst our SVR (MAE 8.58, PW20 46.56) was
the best.
Unlike most statistical models, neural networks are considered to be good at learning feature representations automati-
cally, which is especially useful when there are many features. The IWPC dataset has very few parameters compared
to typical deep learning datasets. Moreover, these parameters are heavily-engineered during the preprocessing stage,
which likely minimises any effects of the representation learning. It is also widely held that NN performance scales
with the size of the dataset and the number of hidden layers [37]. Because the IWPC dataset contains very few records
(by deep learning standards) using more than one hidden layer has little-to-no effect. These factors may explain why
the NN consistently failed to perform on both datasets.
Our results replicate the findings of Ma et al. [12] for LR, SV, and ridge regression (RR) algorithms. But, despite
replicating the implementations outlined in their methodology, our results for NN, gradient boosting trees (GBT),
Stacked SV, and Stacked RR were notably dissimilar. In the case of the ensemble models, this was likely due to their
decision to use a much larger parameter set on their stacked implementations than they fed to other models. In contrast,
our study made use of the same parameters across all models (as standardised by notable previous works [16, 5]).
Another factor may have been the difference in GBT implementations (Scikit-learn vs. LightGBM) between studies.
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This discrepancy once again affirms the need for a standardised set of tools for replicating and evaluating warfarin
dosing models.
Despite the difference in absolute scores between studies, the stacked ensembles were still among the top performers on
the IWPC data, with the Stacked SV in particular achieving an MAE of 8.55 and a PW20 of 46.32. This supports the
use of the stacked generalisation approach to improve warfarin dose estimation. However, with a much smaller effect
size than Ma et al. reported, it may be difficult to justify the use of these techniques over the more-explainable linear
regression model in clinical deployment.
Despite the absence of pharmacogenetic data and many clinical parameters in the PathCare dataset, the traditional
algorithms performed reasonably well. LR (MAE 10.98, PW20 34.08) and SV (MAE 10.93, PW20 34.40) top the
list, along with the Stacked SV ensemble (MAE 10.93, PW20 34.45). However, there was very little variation in
performance on the PathCare dataset amongst the traditional algorithms. We suspect that the very limited parameters in
the dataset result in an early performance plateau. Algorithms with higher bias, like LR and SV, seem to reach that
performance level effectively, whereas algorithms with lower bias appear more prone to overfitting.
3.3 Performance of evolved architectures
The architectures developed using a genetic programming approach (TPOT) had extremely varied results depending on
which dataset they were evolved on.
TPOT C was an estimator pipeline evolved on the IWPC dataset that produced the best results of the evolved models
(MAE 8.56, PW20 46.08). It was only marginally outperformed by the SV and Stacked SV approaches, but outperformed
the Stacked RR estimator on the IWPC dataset. The structure and hyperparameters of the estimator are illustrated in
Figure 2.
Architectures evolved on the IWPC dataset (A, B, and C) performed well on the IWPC dataset. This is remarkable
when considering that they were generated with no human tuning. It is remarkable that three different evolutionary
histories converged to have such similar performance. This result concurs with previous findings [22, 23] that autoML
can attain results comparable to those of models engineered by experts with domain knowledge.
Generally, the TPOT architectures that performed well on the IWPC data also performed well on the PathCare data.
This could indicate that the IWPC dataset captures sufficient information about the parameter-target relationships to
generalise, but may also be a result of limitations in the PathCare dataset.
The architectures evolved on the PathCare dataset (D through H) performed significantly worse than those evolved on
the IWPC dataset (A through C) regardless of which dataset they were trained and evaluated on. This suggests that the
PathCare dataset has a lower ratio of signal to noise compared to the IWPC dataset. These results support prior claims
[38, 39, 40] that pharmacogenetic parameters may be essential for generalisable warfarin dose estimation.
All but one of the architectures evolved with TPOT utilised stacking at some point in their pipelines. This may reflect
a general tendency within the TPOT implementation but, when considered with the high performance of Ma et al.’s
stacked ensembles, may indicate the robustness of stacking for warfarin dose estimation.
Only TPOT C (the best overall) and TPOT E included SVR in their pipelines. This is strange considering the high level
of performance seen with SVR across both datasets. TPOTs B and C (high performers on the IWPC dataset) made
use of trees (with boosting) and/or lasso regression. TPOTs D-H (evolved on PathCare) all relied on a KNN regressor
somewhere in their pipeline, but performed poorly across datasets.
3.4 Limitations
The IWPC dataset was compiled by 22 research groups, each with different protocols and equipment. This resulted in
noisy data and some missing values, which lower the predictive accuracy of models. It is also known that the impact
of CYP2C9 and VKORC1 genes varies across races [5]. Current pharmacogenetic data is mostly derived from White
and Asian OMB racial groups in developed nations (where genetic testing is available), so it is likely that current
pharmacogenetic implementations impart bias upon models.
The PathCare dataset did not include clinical information such as height, weight, and race—all of which have been
shown to improve dosing accuracy. It would, therefore, be imprudent to extrapolate very much from the performance
differences of models on this dataset. Moreover, because the parameters differed from those of the IWPC dataset, it
was not possible to directly train models on one dataset and evaluate their performance on another. It was, however,
possible to evolve the architectures and hyperparameters on one dataset and then train and evaluate models on the other
dataset–which was done and is presented in Table 4.
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Figure 2: Illustration of the highest-performing architecture and hyperparameters evolved on the IWPC dataset using
TPOT. The Python implementation of this architecture can be found along with the project source code.
There are also technical limitations in the performance of the genetic programming tools. As Olson et al. point out
themselves, TPOT becomes quite slow as the size of a dataset increases. Even on the tiny (by machine learning
standards) IWPC dataset, a single run could take days to complete. There are plans to integrate other autoML libraries
and heuristics to seed the populations with strong pipelines and reduce the time to convergence [23].
Unlike linear regression, the other models do not produce human-interpretable formulae for clinical warfarin dosing.
However, trained models could be used to run inference on real patient data and produce dosage recommendations
to help guide clinicians. Further work is needed to produce robust models that can be deployed as decision-support
systems in a clinical context.
12
A PREPRINT - JULY 24, 2020
4 Conclusions
This study presented the Warfit-learn software framework, which implements the best published techniques for warfarin
dosage modelling. The framework was validated by replicating the results of several prior studies on the same IWPC
dataset. Warfit-learn’s parallel evaluation methodology was utilised to compare the performance of several estimators
across both the IWPC dataset and a novel dataset of South African patients provided by PathCare. The estimators
included traditional learning algorithms that have shown promise in warfarin dosing, two stacked generalisation
ensembles described in previous work, and a collection of learning pipelines evolved using a genetic programming
approach to architecture and hyperparameter optimisation.
As in previous studies, linear regression was shown to be a reliable technique. Support vector regression was the best
performing traditional algorithm, whilst neural networks performed poorly. Recent ensemble approaches—namely
stacked generalisation—were shown to be effective across datasets, but the effect size was not as large as previously
reported.
This study found that genetic programming was effective at evolving robust architectures and hyperparameters for
warfarin dosage modelling. All three of the estimators evolved on the IWPC dataset were amongst the top-performing
models, performing on par with the best expert-designed ensembles. Inspection of the architectures revealed a preference
for stacked ensembles. If these results are not unique to warfarin dosing, they suggests that automated machine learning
may be a promising method for the future of software-assisted dosing. These findings should be explored on other
dosage estimation problems in future work. Other advances in this domain can be made by compiling comprehensive
warfarin dosing datasets from more diverse cohorts, and using them to train robust models for safe clinical deployment.
In addition to the performance comparisons and evolutionary optimisation techniques, this paper presented a much-
needed software framework for evaluating new techniques on the IWPC dataset. Warfit-learn eliminates the need for
future researchers to re-create tools, and maintains consistency by providing a standardised testbed. It is our hope that
Warfit-learn will make future studies significantly easier and more reproducible.
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